Based on the smaller tumor size with i.t. injections of the elevated serum CCL2, showing that the antibody injections are working as expected and that there is a good exposure to agents via i.t. injections in this model, we selected i.t. injections at 1 mg/kg of anti-CCL2 antibody for further in vivo experiments. The gene discussed is CCL2; the disease is neoplasm.